ABIO - ARCAバイオファ―マ (ARCA biopharma Inc.) ARCAバイオファ―マ

 ABIOのチャート


 ABIOの企業情報

symbol ABIO
会社名 ARCA biopharma Inc. (ARCAバイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 医薬品   医療関連(Health Care)
概要 事業概要 エーアルシーエー・バイオファマ(ARCA biopharma Inc.)は主に心不全及びその他心臓血管疾患のための遺伝子をターゲットにした治療法の開発に従事するバイオ医薬品企業。同社の主要候補製品の「Gencaro TM(ブシンドロール塩酸塩)」は、慢性心不全(HF)治療のために開発されている薬理学的特性を持つβ[ベータ]遮断薬及び血管拡張剤である。同社はLabCorp社と提携して、「Gencaro」に対する臨床反応を予測できる遺伝子マーカーのためのコンパニオン・テストであるGencaroテストを行っていた。同社の候補製品は「Gencaro(ブシンドロール塩酸塩)」は、慢性心不全(HF)治療のために開発されている薬理学的特性を持つβ[ベータ]遮断薬及び血管拡張剤である。「Gencaro」は心臓神経系においてβ-1とβ-2両方の受容体を遮断する性質を持っているため、β遮断薬クラスの化合物の一部として見なされる。これらの受容体の遮断を通して、「Gencaro」はこれらの受容体を活性化する用のその他分子との結合を防ぐ。   ARCAバイオファ―マは、米国のバイオ医薬品企業。心血管疾患の遺伝的標的治療の開発を中心に事業を展開。主要製品候補として、心不全および左心室機能障害の患者向けに心房細動治療のためのβ遮断薬、および軽度の血管拡張剤であるGencaro(ブシンドロ―ル塩酸塩)の開発を手掛ける。   ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement for a single Phase 3 clinical trial. ARCA is also developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically targeted treatment for heart failure and peripheral arterial disease.
本社所在地 11080 CirclePoint Road Suite 140 Westminster CO 80020 USA
代表者氏名 Robert E. Conway ロバート・E・コンウェイ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 720-940-2200
設立年月日 33817
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 14人
url http://arcabio.com/
nasdaq_url https://www.nasdaq.com/symbol/abio
adr_tso
EBITDA EBITDA(百万ドル) -13.67700
終値(lastsale) 0.6301
時価総額(marketcap) 8773402.1325
時価総額 時価総額(百万ドル) 8.61467
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -1.02033
当期純利益 当期純利益(百万ドル) -13.48100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Arca Biopharma Inc revenues was not reported. Net loss decreased 51% to $4.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.07 to -$0.35.

 ABIOのテクニカル分析


 ABIOのニュース

   ARCA biopharma GAAP EPS of -$0.22 (NASDAQ:ABIO)  2022/08/02 21:15:58 Seeking Alpha
ARCA biopharma press release (NASDAQ:ABIO): Q2 GAAP EPS of -$0.22.
   ARCA biopharma Announces Second Quarter 2022 Financial Results  2022/08/02 20:15:00 GlobeNewswire
WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update.
   ARCA biopharma: Pressure May Make This A Liquidation Play (NASDAQ:ABIO)  2022/05/03 15:50:48 Seeking Alpha
Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Click here to learn more about ABIO stock.
   ARCA biopharma GAAP EPS of -$0.23 (NASDAQ:ABIO)  2022/05/02 20:57:31 Seeking Alpha
ARCA biopharma press release (ABIO): Q1 GAAP EPS of -$0.23.Cash and cash equivalents were $49.1 million as of March 31, 2022, compared to $53.4 million as of December 31, 2021
   ARCA biopharma Announces First Quarter 2022 Financial Results  2022/05/02 20:15:00 GlobeNewswire
WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update.
   ARCA biopharma GAAP EPS of -$0.22 (NASDAQ:ABIO)  2022/08/02 21:15:58 Seeking Alpha
ARCA biopharma press release (NASDAQ:ABIO): Q2 GAAP EPS of -$0.22.
   ARCA biopharma Announces Second Quarter 2022 Financial Results  2022/08/02 20:15:00 GlobeNewswire
WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update.
   ARCA biopharma: Pressure May Make This A Liquidation Play (NASDAQ:ABIO)  2022/05/03 15:50:48 Seeking Alpha
Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Click here to learn more about ABIO stock.
   ARCA biopharma GAAP EPS of -$0.23 (NASDAQ:ABIO)  2022/05/02 20:57:31 Seeking Alpha
ARCA biopharma press release (ABIO): Q1 GAAP EPS of -$0.23.Cash and cash equivalents were $49.1 million as of March 31, 2022, compared to $53.4 million as of December 31, 2021
   ARCA biopharma Announces First Quarter 2022 Financial Results  2022/05/02 20:15:00 GlobeNewswire
WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update.
   ARCA biopharma''s Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study  2022/04/01 11:09:26 Benzinga
ARCA biopharma Inc (NASDAQ: ABIO ) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19. In the 160-patient trial, both doses of rNAPc2 demonstrated a treatment benefit; however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D-dimer level from Baseline to Day 8 … Full story available on Benzinga.com
   ABIO stock falls as COVID-19 trial fails to meet key goal (NASDAQ:ABIO)  2022/03/31 20:42:14 Seeking Alpha
Arca Biopharma (ABIO) is trading ~28% lower in the post-market Thursday after the clinical-stage biotech announced that its experimental COVID-19 therapy rNAPc2 failed to meet the…
   ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial  2022/03/31 20:15:00 GlobeNewswire
WESTMINSTER, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced results for ASPEN-COVID-19 , a 160 patient Phase 2b clinical trial evaluating rNAPc2, a highly potent and specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D-dimer level from Baseline to Day 8 compared to standard of care heparin.
   ARCA biopharma GAAP EPS of -$1.39 (NASDAQ:ABIO)  2022/03/14 21:40:36 Seeking Alpha
ARCA biopharma press release (ABIO): FY GAAP EPS of -$1.39.FY Cash and cash equivalents of $53.4M
   ARCA biopharma Inc Shares Approach 52-Week Low - Market Mover  2022/01/09 19:19:27 Kwhen Finance
ARCA biopharma Inc (ABIO) shares closed today at 1.5% above its 52 week low of $2.01, giving the company a market cap of $29M. The stock is currently down 5.1% year-to-date, down 51.7% over the past 12 months, and down 96.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 1.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -45.1% The company's stock price performance over the past 12 months lags the peer average by -1436.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

 関連キーワード  (医薬品 米国株 ARCAバイオファ―マ ABIO ARCA biopharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)